Due to the low pCR rate of neoadjuvant therapy for HR–positive breast cancer, some researchers have proposed using residual tumor Ki67 level instead of pCR as the index for evaluating response to neoadjuvant endocrine therapy. Here, MKI67 is linked to breast cancer.